glp 1 patent Ozempic's problem: how Novo Nordisk lost control of a blockbuster drug. ๐ Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite China patent expiry and new
Pay in 4 interest-free payments of $6.12 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 20 - Aug 25



























